# Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

> **NCT00467584** · PHASE3 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 62 (actual)

## Conditions studied

- Multiple Sclerosis
- Fatigue

## Interventions

- **DRUG:** High Dose Aspirin (1300 mg/day)
- **DRUG:** Low Dose Aspirin (162 mg/day)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00467584
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Interim analysis indicated treatment unlikely effective;slow recruitment
- **Last updated:** 2014-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00467584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00467584, "Aspirin for Treatment of Multiple Sclerosis-Related Fatigue". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00467584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*